GlassScriptPhysician profile
Susan Melnick
NPI 1366565202
$1,312.45
in general payments reported to CMS, 2019-2025
11 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical General Practice (Registered Nurse) provider received nationally (typical 2025 total: $110).
See the full distribution for General Practice (Registered Nurse)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $321 · 2022: $462 · 2023: $172 · 2024: $83.57 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $529.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $249.38 | 2021-2023 | |
| Alkermes, INC. | $247.82 | 2021-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $186.89 | 2022-2025 | Uzedy, Austedo |
| Lundbeck LLC | $126.60 | 2022-2024 | Rexulti |
| Abbvie INC. | $104.29 | 2022-2023 | |
| Vanda Pharmaceuticals INC. | $99.01 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $92.58 | 2024-2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $67.45 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $65.68 | 2021-2025 | Capvaxive, Gardasil 9 |
| Pfizer INC. | $44.00 | 2025 | |
| Nevro Corp. | $28.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Melnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.